Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 4, 2020 (6 years ago)

Nystatin Oral Suspension

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Subpotent drug: Out of specification for assay at the 15-month test interval.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl. oz. (473 mL), Rx only, Pharmaceutical Associates, Inc. Greenville, SC 29605, NDC 0121-0810-16

Affected NDC 0121-0810-16

Compare with the code on your package — it is the most precise check available.

Drug: Nystatin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Nystatin
NDC 00121-0810
100000 [USP'U]/mL Suspension
Oral
Pharmaceutical Associates, Inc. Rx
Recalling firm
PAI Holdings, LLC. dba Pharmaceutical Associates Inc
NDC code
0121-0810-16
Origin
SC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1494-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Nystatin recalls

See all
Class II · Moderate risk

Nystatin Cream USP

Subpotent Drug: Low out of specification assay results performed during long-term stability testing.

Ongoing Wrong potency / content Padagis US LLC NDC 45802-059-35 D-0677-2026
Class II · Moderate risk

Nystatin 150 Mu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-1 D-0157-2024
Class II · Moderate risk

Nystatin 2 Bu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-4 D-0156-2024
Class II · Moderate risk

Nystatin 500 Mu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-3 D-0155-2024

Other recalls by PAI Holdings, LLC. dba Pharmaceutical Associates Inc

All 2020 recalls
Class II · Moderate risk

VistaPharm

Does Not Meet USP or OTC Monograph: Product did not meet the Over-the-Counter (OTC) Monograph M023

Ongoing Unapproved drug PAI Holdings LLC NDC 66689-203-08 D-0592-2026
Class II · Moderate risk

VistaPharm

Does Not Meet USP or OTC Monograph: Product did not meet the Over-the-Counter (OTC) Monograph M023

Ongoing Unapproved drug PAI Holdings LLC NDC 66689-203-04 D-0591-2026
Class II · Moderate risk

VistaPharm

Does Not Meet USP or OTC Monograph: Product did not meet the Over-the-Counter (OTC) Monograph M023

Ongoing Unapproved drug PAI Holdings LLC NDC 66689-202-08 D-0590-2026
Class II · Moderate risk

VistaPharm

Does Not Meet USP or OTC Monograph: Product did not meet the Over-the-Counter (OTC) Monograph M023

Ongoing Unapproved drug PAI Holdings LLC NDC 66689-202-04 D-0589-2026